Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
<p>Abstract</p> <p>The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin sys...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-03-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | http://www.dmsjournal.com/content/4/1/8 |
| _version_ | 1811252968958197760 |
|---|---|
| author | Cobble Michael |
| author_facet | Cobble Michael |
| author_sort | Cobble Michael |
| collection | DOAJ |
| description | <p>Abstract</p> <p>The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin system to regulate glucose homeostasis, there are important clinical differences among the five agents currently available in the U.S. For example, the GLP-1R agonists require subcutaneous administration, produce pharmacological levels of GLP-1 activity, promote weight loss, have a more robust glucose-lowering effect, and have a higher incidence of adverse gastrointestinal effects. In contrast, the DPP-4 inhibitors are taken orally, increase the half-life of endogenous GLP-1, are weight neutral, and are more commonly associated with nasopharyngitis. Differences in efficacy, safety, tolerability, and cost among the incretin-based therapies are important to consider in the primary care management of patients with type 2 diabetes mellitus.</p> |
| first_indexed | 2024-04-12T16:43:44Z |
| format | Article |
| id | doaj.art-e08a47d38f594dde8be3a9309c504db2 |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-04-12T16:43:44Z |
| publishDate | 2012-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-e08a47d38f594dde8be3a9309c504db22022-12-22T03:24:41ZengBMCDiabetology & Metabolic Syndrome1758-59962012-03-0141810.1186/1758-5996-4-8Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitusCobble Michael<p>Abstract</p> <p>The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin system to regulate glucose homeostasis, there are important clinical differences among the five agents currently available in the U.S. For example, the GLP-1R agonists require subcutaneous administration, produce pharmacological levels of GLP-1 activity, promote weight loss, have a more robust glucose-lowering effect, and have a higher incidence of adverse gastrointestinal effects. In contrast, the DPP-4 inhibitors are taken orally, increase the half-life of endogenous GLP-1, are weight neutral, and are more commonly associated with nasopharyngitis. Differences in efficacy, safety, tolerability, and cost among the incretin-based therapies are important to consider in the primary care management of patients with type 2 diabetes mellitus.</p>http://www.dmsjournal.com/content/4/1/8type 2 diabetesexenatideliraglutidesitagliptinsaxagliptinlinagliptinefficacysafety |
| spellingShingle | Cobble Michael Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus Diabetology & Metabolic Syndrome type 2 diabetes exenatide liraglutide sitagliptin saxagliptin linagliptin efficacy safety |
| title | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| title_full | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| title_fullStr | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| title_full_unstemmed | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| title_short | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| title_sort | differentiating among incretin based therapies in the management of patients with type 2 diabetes mellitus |
| topic | type 2 diabetes exenatide liraglutide sitagliptin saxagliptin linagliptin efficacy safety |
| url | http://www.dmsjournal.com/content/4/1/8 |
| work_keys_str_mv | AT cobblemichael differentiatingamongincretinbasedtherapiesinthemanagementofpatientswithtype2diabetesmellitus |